Branded Wegovy (injection) Cash-pay only The telemedicine subscription is month-to-month and can be canceled
Frias Researchers conducted a phase 2a randomized, double-blind, active-controlled trial
Fukabori, Y
N Engl J Med 2025;393:1796-1806 [9] Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial, December 2025: Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company [10] Fourth High-level Meeting of the UN General Assembly on the prevention and control of NCDs and the promotion of mental health and wellbeing (HLM4), September 2025: [11] Thousands of patients from Scotlands poorest areas to benefit from landmark UK government-funded obesity study, November 2025: Thousands of patients from Scotlands poorest areas to benefit from landmark UK government-funded obesity study - GOV.UK [12] Non-Traditional Channels: The Compounded GLP-1 Market

adults currently taking GLP-1 medications for weight loss has climbed to 11% in 2026, up from 3% just two years ago
This means it stimulates the pituitary gland to produce hormones and helps deliver them to the bloodstream